Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study
Bunick C, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study. Clinical And Experimental Dermatology 2023, 48: 765-769. PMID: 36928932, DOI: 10.1093/ced/llad105.Peer-Reviewed Original ResearchConceptsBSA involvementCongenital ichthyosisHigher DLQIIgA responsesTreatment successControl studyDermatology Life Quality Index scoresBody surface area involvementDose-limiting adverse effectGlobal assessmentLife Quality Index scoresInvestigator's Global AssessmentSurface area involvementProportion of participantsRating Scale scoresSystemic retinoid treatmentYears of ageQuality Index scoresCharacteristics of participantsIgA respondersBaseline demographicsEfficacy endpointMedian ageArea involvementScale score